Clinical Trial

Semaglutide Treatment in Type 1 Diabetes

Study acronym: OBES1TY
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-26; most recent amendment 2025-08-04.
Trial Details
NCT Number NCT06909006
Lead Sponsor Nordsjaellands Hospital
Collaborators: Steno Diabetes Center Copenhagen, Steno Diabetes Center Odense, Zealand University Hospital, Aarhus University Hospital
Conditions Obesity in Diabetes, Obesity/Therapy, Type 1 Diabetes Mellitus (T1DM), Insulin Sensitivity/Resistance, Semaglutide, Lipidomics, Metabolomics, Weight Loss +1 more
Enrollment 122 participants
Start Date 2025-10
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-08-08